Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of locally advanced or metastatic clear cell renal cell carcinoma (a specific type of kidney cancer), confirmed by laboratory tissue analysis.
- For part 1 of the trial: People who have already received at least two different treatment plans in the past, which must have included both an immunotherapy and a targeted therapy.
- For part 2 of the trial: People who have previously completed at least one standard treatment plan that included both a specific type of immunotherapy (a PD-1/L1 inhibitor) and a specific type of targeted therapy (a VEGF-TKI), whether given together or one after the other.
- People who are generally able to carry out everyday activities with no or minimal limitations, as measured by a standard medical scale called the ECOG performance status (scores 0 or 1).
Who may not be able to join:
- People who are unable to swallow tablets or capsules whole, or who cannot tolerate oral (swallowed) medication in its standard form without chewing, breaking, or crushing it.
- For part 2A specifically: People who have already received more than three systemic (whole-body) treatment plans for their kidney cancer, or who have previously been treated with a type of drug called a HIF2a inhibitor.
- People who have low blood oxygen levels, defined as a reading below 92% on a pulse oximeter while at rest, or who need supplemental oxygen either occasionally or on an ongoing basis.
- People who have received certain medications used to stimulate blood cell production (such as G-CSF, GM-CSF, or synthetic EPO) within the 28 days before the first dose of the trial treatment.
- Additional eligibility requirements set out in the trial protocol also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Adverse Events (AEs); Number of Participants With Serious Adverse Events (SAEs); Number of Participants With AEs Meeting Protocol Defined Dose-limiting Toxicity (DLT) Criteria; Number of Participants With AEs Leading to Discontinuation; Number of Participants With AEs Leading to Deaths as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.